Skip to nav Skip to content
  • Overview

    Cancer Focus:
    Basal Cell Carcinoma, GIST (Gastrointestinal Stromal Tumor), Melanoma, Merkel Cell Carcinoma, Osteosarcoma, Sarcoma, Skin Cancer (Nonmelanoma), Squamous Cell Carcinoma

    Dr. Andrew (Andy) Brohl is a medical oncologist and physician-scientist.  His clinical interest is in the care of patients with a diagnosis of sarcoma or a cutaneous (skin) malignancy, including melanoma. Dr. Brohl’s laboratory research focuses on the utilization of genomics and other high-throughput technologies to learn more about rare cancers and for clinically translational applications. Examples of his current projects include genomic analysis of rare cancer subtypes, identification of drug targets from “-omics” datatypes, application of genomics for personalized cancer therapy, and development of non-invasive molecular profiling technology. Additionally, he is a member of the analysis team for the National Institutes of Health’s “The Cancer Genome Atlas” (TCGA) sarcoma project. Dr. Brohl earned his MD degree from the University of Miami, Miller School of Medicine. He completed an Internal Medicine Residency at Georgetown University and a Hematology and Medical Oncology Fellowship at the National Cancer Institute. He joined Moffitt in 2015 from the Icahn School of Medicine at Mount Sinai where he held dual academic appointments in the Department of Genetics and Genomic Science and the Division of Hematology and Medical Oncology. Dr. Brohl has received numerous academic awards including graduation with research distinction and magna cum laude from Duke University. Also while at Duke, he was named to the Tau Beta Pi engineering honor society, was selected as a Pratt Engineering Undergraduate Fellow, and graduated with dual majors in Biomedical Engineering and Mathematics. During medical school, he was recognized for academic and service contributions, including post-Hurricane Katrina volunteer efforts in southern Mississippi, and was named to the Alpha Omega Alpha medical honor society. Dr. Brohl is currently a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society, the Society for Immunotherapy of Cancer, and the American Society of Clinical Oncology. 

    Education & Training

    Board Certification:

    • Internal Medicine - Medical Oncology


    • National Cancer Institute - Hematology and Oncology


    • Georgetown University - Internal Medicine

    Medical School:

    • University of Miami Miller School of Medicine - MD
  • Participating Trials

    Clinical Trial 20773
    Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
    Condition: Cutaneous
    Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)
    Status: Open

    Clinical Trial 21105
    A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of INBRX-109 as Any-line Therapy in Conventional Chondrosarcoma
    Condition: Sarcoma
    Intervention: INBRX-109 (); Placebo ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open. 2024 May.9(5):103461. Pubmedid: 38744102. Pmcid: PMC11108812.
    • Tometich DB, Geiss C, Maconi ML, Chavez M, Hoogland AI, Li X, Nieves-Lopez A, Rodriguez Y, Bryant C, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Hwu P, Khushalani NI, Jim HSL. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study. Support Care Cancer. 2024 May.32(6):330. Pubmedid: 38709312.
    • Jinesh GG, Smallin MT, Mtchedlidze N, Godwin I, Napoli M, Hackel N, Phadke MS, Deshpande AA, Li X, Lockhart JH, Baldwin JR, Acevedo-Acevedo S, Gao Y, Reiser MA, Smalley KSM, Flores ER, Brohl AS. C19MC miRNA-520G induces SP100 antiviral gene transcription and inhibits melanin production in skin cutaneous melanoma. Genes Dis. 2024 Jan.11(1):60-63. Pubmedid: 37588194. Pmcid: PMC10425800.
    • Baginska J, Nau A, Gomez Diaz I, Giobbie-Hurder A, Weirather J, Vergara J, Abrecht C, Hallisey M, Dennis J, Severgnini M, Huezo J, Marciello I, Rahma O, Manos M, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Ott PA, Buchbinder EI, Hodi FS. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Cancer Immunol Immun. 2024 Jan.73(1):17. Pubmedid: 38236249. Pmcid: PMC10796592.
    • Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani NI, Smalley KSM. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma. Cancer. 2024 Jan.130(2):232-243. Pubmedid: 37776537.
    • Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. First-in-human stage III/IV melanoma​ clinical trial of immune priming agent IFx-Hu2.0. Mol Cancer Ther. 2024 Apr. Pubmedid: 38657233.
    • Welch DL, Fridley BL, Cen L, Teer JK, Yoder SJ, Pettersson F, Xu L, Cheng CH, Zhang Y, Alexandrow MG, Xiang S, Robertson-Tessi M, Brown JS, Metts J, Brohl AS, Reed DR. Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy. Sci Rep. 2023 Nov.13(1):20125. Pubmedid: 37978271. Pmcid: PMC10656496.
    • Marin-Acevedo JA, Withycombe BM, Kim Y, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Tsai KY, Khushalani NI. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers (Basel). 2023 Jun.15(12). Pubmedid: 37370790. Pmcid: PMC10295991.
    • Miao R, Swank J, Melzer D, Ludlow S, Clark L, Finger M, Reed DR, Druta M, Brohl AS. Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?. Cancer Immunol Immun. 2023 Jul.72(7):2521-2527. Pubmedid: 36912932. Pmcid: PMC10264480.
    • Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour AP, Li S, Nguyen TL, Fatkin D, Graham RM, Giannoulatou E, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Cuppen E, van Eijk K, Veldink J, Ahn JH, Kim JE, Randall RL, Tucker K, Judson I, Sarin R, Ludwig T, Genin E, Deleuze JF, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM, Tattersall M, Neuhaus S, Lewis C, Tucker K, Carey-Smith R, Wood D, Porceddu S, Dickinson I, Thorne H, James P, Ray-Coquard I, Blay JY, Cassier P, Le Cesne A, Duffaud F, Penel N, Isambert N, Kurtz JE, Puri A, Sarin R, Ahn JH, Kim JE, Ward I, Judson I, van der Graaf W, Seddon B, Chandrasekar C, Rickar R, Hennig I, Schiffman J, Randall RL, Silvestri A, Zaratzian A, Tayao M, Walwyn K, Niedermayr E, Mang D, Clark R, Thorpe T, MacDonald J, Riddell K, Mar J, Fennelly V, Wicht A, Zielony B, Galligan E, Glavich G, Stoeckert J, Williams L, Djandjgava L, Buettner I, Osinki C, Stephens S, Rogasik M, Bouclier L, Girodet M, Charreton A, Fayet Y, Crasto S, Sandupatla B, Yoon Y, Je N, Thompson L, Fowler T, Johnson B, Petrikova G, Hambridge T, Hutchins A, Bottero D, Scanlon D, Stokes-Denson J, Génin E, Campion D, Dartigues JF, Deleuze JF, Lambert JC, Redon R, Ludwig T, Gr ...
    • Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
    • Miao R, Bui MM, Walko C, Mullinax JE, Brohl AS. A Malignant Glomus Tumor of the Liver Harboring MIR143-NOTCH2 Rearrangement: From Diagnosis to Management. Cureus. 2022 Oct.14(10):e30718. Pubmedid: 36439569. Pmcid: PMC9696860.
    • Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022 Nov.10(11). Pubmedid: 36450385. Pmcid: PMC9717375.
    • Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May.8(5):740-747. Pubmedid: 35357396. Pmcid: PMC8972152.
    • Rahma OE, Tyan K, Giobbie-Hurder A, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. J Immunother Cancer. 2022 Mar.10(3). Pubmedid: 35264434. Pmcid: PMC8915279.
    • Fusco MJ, Knepper TC, Balliu J, Del Cueto A, Laborde JM, Hooda SM, Brohl AS, Bui MM, Hicks JK. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. Oncologist. 2022 Feb.27(1):e9-e17. Pubmedid: 35305098. Pmcid: PMC8842368.
    • Jinesh GG, Brohl AS. Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis. Signal Transduct Target Ther. 2022 Aug.7(1):296. Pubmedid: 35999218. Pmcid: PMC9399134.
    • Linkowski LC, Sim AJ, Redler G, Brohl AS, Rosenberg SA, Wuthrick EJ. Delivery of Online Adaptive MRI-Guided Radiation Therapy for a Deaf Patient. Cureus. 2022 Aug.14(8):e27558. Pubmedid: 36059359. Pmcid: PMC9429821.
    • Knepper TC, Panchaud RA, Muradova E, Cohen L, DeCaprio JA, Khushalani NI, Tsai KY, Brohl AS. An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. Cancer Med. 2021 Sep.10(17):5889-5896. Pubmedid: 34269527. Pmcid: PMC8419775.
    • Brohl AS, Sindiri S, Wei JS, Milewski D, Chou HC, Song YK, Wen X, Kumar J, Reardon HV, Mudunuri US, Collins JR, Nagaraj S, Gangalapudi V, Tyagi M, Zhu YJ, Masih KE, Yohe ME, Shern JF, Qi Y, Guha U, Catchpoole D, Orentas RJ, Kuznetsov IB, Llosa NJ, Ligon JA, Turpin BK, Leino DG, Iwata S, Andrulis IL, Wunder JS, Toledo SRC, Meltzer PS, Lau C, Teicher BA, Magnan H, Ladanyi M, Khan J. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Rep. 2021 Nov.37(8):110047. Pubmedid: 34818552. Pmcid: PMC8642810.
    • Jinesh GG, Napoli M, Smallin MT, Davis A, Ackerman HD, Raulji P, Montey N, Flores ER, Brohl AS. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep. 2021 Jun.11(1):12673. Pubmedid: 34135394. Pmcid: PMC8209049.
    • Martín-Broto J, Lopez Pousa A, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 Jan.20(1):132-141. Pubmedid: 33177152.
    • D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021 Dec.6(6):100290. Pubmedid: 34715570. Pmcid: PMC8564559.
    • Sipe BH, Običan SG, Henderson-Jackson E, Riddle ND, Makanji R, Gonzalez RJ, Brohl AS. A Case of Retroperitoneal Synovial Sarcoma in Pregnancy Treated with Antepartum Doxorubicin plus Ifosfamide Chemotherapy. Case Rep Oncol Med. 2021 Aug.2021:9982171. Pubmedid: 34336322. Pmcid: PMC8313357.
    • Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021 Apr.9(4). Pubmedid: 33879601. Pmcid: PMC8061836.
    • Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol. 2020 Sep.16(27):2089-2099. Pubmedid: 32938212. Pmcid: PMC9437770.
    • D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Georges S, Shah P, Ellers-Lenz B, Bajars M, Güzel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020 May.8(1). Pubmedid: 32414862. Pmcid: PMC7239697.
    • Rizk VT, Naghavi AO, Brohl AS, Joyce DM, Binitie O, Kim Y, Hanna JP, Swank J, Gonzalez RJ, Reed DR, Druta M. Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk. Clin Sarcoma Res. 2020 Jul.10:11. Pubmedid: 32670544. Pmcid: PMC7350709.
    • Jinesh GG, Napoli M, Ackerman HD, Raulji PM, Montey N, Flores ER, Brohl AS. Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma. Sci Rep. 2020 Jul.10(1):12371. Pubmedid: 32704163. Pmcid: PMC7378193.
    • Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan.33(1):86-95. Pubmedid: 31329344. Pmcid: PMC6928428.
    • Rybinski B, Wolinsky T, Brohl A, Moerdler S, Reed DR, Ewart M, Weiser D. Multifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring PHOX2B and NF1 genetic aberrations. Gene Chromosome Canc. 2020 Feb.59(2):119-124. Pubmedid: 31515834.
    • Brohl AS, Sondak VK. Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. J Clin Oncol. 2020 Aug.38(22):2471-2475. Pubmedid: 32530767.
    • Moore CE, Monforte H, Teer JK, Zhang Y, Yoder S, Brohl AS, Reed D. TRIM28 congenital predisposition to Wilms' tumor: novel mutations and presentation in a sibling pair. Cold Spring Harb Mol Case Stud. 2020 Aug.6(4). Pubmedid: 32699065. Pmcid: PMC7476416.
    • Weinstein B, Henderson-Jackson E, Cruse CW, Brohl AS. PIK3CA-Related Overgrowth Syndrome (PROS) and Angiosarcoma: A Case Report. Eplasty. 2020 Apr.20:ic6. Pubmedid: 32362992. Pmcid: PMC7180201.
    • Setty BA, Jinesh GG, Arnold M, Pettersson F, Cheng CH, Cen L, Yoder SJ, Teer JK, Flores ER, Reed DR, Brohl AS. The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss. PLoS Genet. 2020 Apr.16(4):e1008642. Pubmedid: 32310940. Pmcid: PMC7192511.
    • Welch D, Kahen E, Fridley B, Brohl AS, Cubitt CL, Reed DR. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines. PLoS One. 2019 Sep.14(9):e0222228. Pubmedid: 31550266. Pmcid: PMC6759167.
    • Geller DS, Levine NL, Hoang BH, Yang R, Weiser D, Morris J, Gorlick R, Gill JB, Roth ME, Tingling J, Brohl AS. Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma. JCO Precis Oncol. 2019 Sep.3. Pubmedid: 32914027. Pmcid: PMC7446473.
    • Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2019 Oct.25(19):5961-5971. Pubmedid: 31399473. Pmcid: PMC6774882.
    • Jinesh GG, Brohl AS. The genetic script of metastasis. Biol Rev Camb Philos Soc. 2019 Oct. Pubmedid: 31663259.
    • Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-Jackson E, Linos K, Baker M, Walko CM, Millis S, Brohl AS. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019 Nov.32(11):1593-1604. Pubmedid: 31189996.
    • Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019 Mar.37(9):693-702. Pubmedid: 30726175. Pmcid: PMC6424137.
    • Rizk VT, Walko CM, Brohl AS. Precision medicine approaches for the management of Ewing sarcoma: current perspectives. Pharmgenomics Pers Med. 2019 Jan.12:9-14. Pubmedid: 30697061. Pmcid: PMC6340366.
    • D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunol Immun. 2019 Apr.68(4):609-618. Pubmedid: 30721341. Pmcid: PMC6447510.
    • Jinesh GG, Flores ER, Brohl AS. Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers. PLoS One. 2018 Oct.13(10):e0206008. Pubmedid: 30335837. Pmcid: PMC6193703.
    • Hicks JK, Henderson-Jackson E, Duggan J, Joyce DM, Brohl AS. Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma. Diagn Pathol. 2018 Oct.13(1):77. Pubmedid: 30314519. Pmcid: PMC6186031.
    • Boddu S, Walko CM, Bienasz S, Bui MM, Henderson-Jackson E, Naghavi AO, Mullinax JE, Joyce DM, Binitie O, Letson GD, Gonzalez RJ, Reed DR, Druta M, Brohl AS. Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: A Single-Center Experience. JCO Precis Oncol. 2018 Nov.2:1-8. Pubmedid: 35135155.
    • Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma. Clin Cancer Res. 2018 Nov.24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
    • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
    • Saller J, Walko CM, Millis SZ, Henderson-Jackson E, Makanji R, Brohl AS. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. J Natl Compr Canc Ne. 2018 Jul.16(7):797-800. Pubmedid: 30006421.
    • Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 Jan.29(1):250-255. Pubmedid: 29045547. Pmcid: PMC5834131.
    • Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O, Brohl AS, Bridge JA, Stavas M, Shinohara ET, Meyer WH, Reed DR, Wagner LM. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb.65(2). Pubmedid: 28905489.
    • Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L. Checkpoint inhibitor-associated cutaneous small vessel vasculitis. JAAD Case Rep. 2018 Aug.4(7):675-677. Pubmedid: 30112452. Pmcid: PMC6092526.
    • Kahen EJ, Brohl A, Yu D, Welch D, Cubitt CL, Lee JK, Chen Y, Yoder SJ, Teer JK, Zhang YO, Wallace MR, Reed DR. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018 Apr.9(32):22571-22585. Pubmedid: 29854299. Pmcid: PMC5978249.
    • Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017 Nov.7(1):14992. Pubmedid: 29118384. Pmcid: PMC5678116.
    • Cancer Genome Atlas Research Network, Brohl AS. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017 Nov.171(4):950-965.e28. Pubmedid: 29100075. Pmcid: PMC5693358.
    • Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun.123(12):2206-2218. Pubmedid: 28323337. Pmcid: PMC5485018.
    • Brohl AS, Patidar R, Turner CE, Wen X, Song YK, Wei JS, Calzone KA, Khan J. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med. 2017 Aug.19(8):955-958. Pubmedid: 28125078. Pmcid: PMC5529247.
    • Hoggard TM, Henderson-Jackson E, Bui MM, Caracciolo J, Teer JK, Yoder S, Binitie O, Gonzalez RJ, Brohl AS, Reed DR. Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy. BMC Cancer. 2017 Apr.17(1):250. Pubmedid: 28390395. Pmcid: PMC5385017.
    • Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep.122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
    • Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep.17(9):1261-1271. Pubmedid: 27498913.
    • Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016 Jun.8(1):62. Pubmedid: 27245685. Pmcid: PMC4888213.
    • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec.4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
    • Chang W, Brohl A, Patidar R, Sindiri S, Shern JF, Wei JS, Song YK, Yohe ME, Gryder BE, Zhang S, Calzone KA, Shivaprasad N, Wen X, Badgett T, Miettinen M, Hartman KR, League-Pascual JC, Trahair T, Widemann BC, Merchant MS, Kaplan RN, Lin JC, Khan J. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res. 2016 Aug.22(15):3810-3820. Pubmedid: 26994145. Pmcid: PMC4970946.
    • Brohl AS, Demicco EG, Mourtzikos K, Maki RG. Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. Clin Sarcoma Res. 2015 Sep.5:21. Pubmedid: 26396737. Pmcid: PMC4578851.
    • Brock CO, Brohl AS, Običan SG. Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. Birth Defects Res C Embryo Today. 2015 Sep.105(3):201-208. Pubmedid: 26396056.
    • Brohl AS, Stinson JR, Su HC, Badgett T, Jennings CD, Sukumar G, Sindiri S, Wang W, Kardava L, Moir S, Dalgard CL, Moscow JA, Khan J, Snow AL. Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis. J Clin Immunol. 2015 Jan.35(1):32-46. Pubmedid: 25352053. Pmcid: PMC4466218.
    • Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015 Apr.20(4):433-439. Pubmedid: 25765878. Pmcid: PMC4391766.
    • Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014 Jul.10(7):e1004475. Pubmedid: 25010205. Pmcid: PMC4091782.
    • Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb.4(2):216-231. Pubmedid: 24436047. Pmcid: PMC4462130.
    • Solomon DA, Brohl AS, Khan J, Miettinen M. Clinicopathologic features of a second patient with Ewing-like sarcoma harboring CIC-FOXO4 gene fusion. Am J Surg Pathol. 2014 Dec.38(12):1724-1725. Pubmedid: 25321332. Pmcid: PMC4229425.
    • Farid M, Ahn L, Brohl A, Cioffi A, Maki RG. Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. Sarcoma. 2014 Apr.2014:617102. Pubmedid: 24693222. Pmcid: PMC3945465.
    • Brohl AS, Song JY, Lieberman R, Gause B. Synchronous indolent primary gastrointestinal lymphomas managed successfully with conservative measures. Am J Ther. 20(5):549-553. Pubmedid: 22020085. Pmcid: PMC3266981.
    • Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. Cancer Control. 24(5):1073274817729070. Pubmedid: 28975823. Pmcid: PMC5937239.
  • Grants

    Title: Oncogenic role of the chromosome 19 microRNA cluster in soft tissue sarcoma
    Sponsor: US Army
    PI: Brohl, A.
    Title: Immune correlates of response to neoadjuvant treatment of Merkel cell carcinoma with pembrolizumab plus Lenvatinib
    Sponsor: Merck & Co., Inc.
    PI: Brohl, A.
    Title: Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers
    Sponsor: Nat Institutes of Health
    PI: Brohl, A.
  • Patient Comments

    Overall Satisfaction


    130 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor